StemRIM (TYO:4599)
Japan flag Japan · Delayed Price · Currency is JPY
123.00
+1.00 (0.82%)
Nov 18, 2026, 10:19 AM JST

StemRIM Company Description

StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally.

The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, acute ischemic stroke, cerebral infarction, myocardial infarction/cardiomyopathy, chronic liver disease, and knee osteoarthritis.

It also develops TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a gene therapy for the treatment of epidermolysis bullosa.

The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.

StemRIM
CountryJapan
Founded2006
IndustryBiotechnology
SectorHealthcare
Employees48
CEOMasatsune Okajima

Contact Details

Address:
Saito Bio-Incubator
Ibaraki, 567-0085
Japan
Phone81 72 648 7152
Websitestemrim.com

Stock Details

Ticker Symbol4599
ExchangeTokyo Stock Exchange
Fiscal YearAugust - July
Reporting CurrencyJPY
ISIN NumberJP3399690001
SIC Code2836

Key Executives

NamePosition
Masatsune OkajimaChief Executive Officer